

June 29, 2020
NOTICE TO THE PUBLIC

RFQ#1228871

The Food and Drug Administration (FDA) seeks competitive offers which will be awarded via a purchase order.

Project Title

Creation of Rfwd2-Targeted Embryonic Stem Cell Lines

Period of Performance

One (1) year from award of the purchase order

Statement of Work

Scope of work

FDA requires the creation of a conditional *Rfwd2* knockout mouse model using targeted embryonic stem (ES) cell lines that FDA will supply to the contractor. This mouse model will be used to test the function of monoclonal antibody products in vivo.

Deliverables

Quantity	Type	Specifics
3 pairs of breeding mice	<i>Rfwd2</i> -floxed heterozygous female mice and <i>Rfwd2</i> -floxed homozygous male mice	C57BL/6 Background with <i>Rfwd2</i> gene floxed and deletion of the Neomycin cassette.

Contractor shall provide genetic evidence that the conditional knockout mice have been successfully created. Upon receipt of the mice at the Agency, FDA will then further breed the mice with Cre-expressing mouse lines to generate tissue-specific *Rfwd2* knockout mouse models.

SALIENT CHARACTERISTICS

The FDA is seeking a contractor that has the capability to produce a mouse line from *Rfwd2*-targeted ES cells that will be provided by FDA. *Rfwd2*-targeted mouse ES cell lines were generated on C57BL/6 background. The *Rfwd2*-targeted ES cell line will be used for blastocysts injection and chimeric mouse generation. The Neomycin cassette in the chimeric mice will be deleted by breeding the chimera with FLP deleter strain on C57BL/6 background. FDA require three pairs of breeding mice with the following characteristics:

June 29, 2020
NOTICE TO THE PUBLIC

RFQ#1228871

1. On C57BL/6J mouse background
2. With *Rfwd2*-floxed homozygous for male mice and heterozygous for female mice
3. Can be used for breeding to generate mouse lines with tissue-specific deletion of *Rfwd2* gene

OVERVIEW OF DELIVERABLES

The conditional *Rfwd2* knockout mouse line will be created by the contractor. The mouse line shall be generated by injection of *Rfwd2*-targeted ES cell lines into blastocysts, generation of chimeric mouse, removal of neomycin cassette by breeding the chimera to FLP deleter strain and generation of *Rfwd2*-floxed homozygous male mice and heterozygous female mice.

Contractor shall also provide documentation on the methods and processes used to achieve the final product and all other supporting technical data; to include methods used to confirm knockout of the desired gene.

Place of Performance/ Shipment

Food and Drug Administration
10903 New Hampshire Avenue
Bldg. 52/72, Rm 2380
Silver Spring, MD 20903

Acceptance Criteria

Experimentally mice will be confirmed upon receipt at FDA Laboratory Point of Contact

Special Consideration

1. Contractor shall ship mice the fastest way of delivery (e.g. same day, overnight, etc.)
2. Delivery shall be made on a weekday (Monday-Friday) before 5 pm EST
3. Contractor shall include shipping costs for ES cell line and mouse line deliveries are included in the price

All quotes must be received by 10:00 a.m., Eastern Standard Time on July 6, 2020 via email to Linda Troutman at Linda.Troutman@fda.hhs.gov. The FDA intends to make an award immediately after the response date of this notice. The award will be made in accordance with FAR Part 13, Simplified Acquisition.